STAAR Surgical Company
STAAHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, STAAR Surgical Company focuses on Medical Instruments & Supplies services and products. STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the. The $1.32B market capitalization puts STAA squarely in small-cap range for its industry. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Market Cap
$1.32B
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
26.75
EPS (TTM)
$-0.38
EPS (Fwd)
$0.99
ROE
-6.0%
ROA
0.9%
Cash
$163.9M
Total Debt
$37.3M
Free CF
-$17.5M
52W Change
52.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $163.9M in cash comfortably exceeding the $37.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$17.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -6.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.9% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $284.4M (2022) to $239.4M (2025), a 16% decline worth watching.
With cash comfortably exceeding debt, STAA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STAA.